Pregnancy: a therapeutic dilemma

Area of Science:

• Pharmacology
• Obstetrics
• Teratology

Background:

• Drug use during pregnancy presents significant challenges for both maternal health and fetal development.
• Regulatory agencies like the Food and Drug Administration (FDA) provide drug categorization systems to guide treatment decisions.
• Balancing therapeutic efficacy with potential risks is paramount in managing conditions during gestation.

Purpose of the Study:

• To review the safety profiles of various drug classes commonly considered for use during pregnancy.
• To highlight specific medications and their associated risks or benefits for pregnant individuals and their fetuses.
• To emphasize the importance of precise and safe treatment strategies in prenatal care.

Main Methods:

• Literature review of drug safety data during pregnancy.
• Analysis of FDA drug categories and their implications.
• Evaluation of specific drug classes including antihistamines, retinoids, antimalarials, sulfones, glucocorticosteroids, and cyclosporine A.

Main Results:

• First-generation antihistamines are generally safe but sedating; second-generation antihistamines have varying safety profiles (e.g., cetirizine, loratadine vs. category C).
• Retinoids are contraindicated due to teratogenic risks; antimalarials require case-by-case clinical assessment.
• Sulfones necessitate monitoring; prednisone is used, but other glucocorticosteroids differ in safety; cyclosporine A is for severe cases.

Conclusions:

• Treatment decisions during pregnancy require careful consideration of drug-specific risks and benefits.
• Adherence to FDA guidelines and individualized patient monitoring is essential for safe and effective prenatal pharmacotherapy.
• Prioritizing fetal safety alongside maternal well-being is the cornerstone of managing medical conditions during pregnancy.